Addex Therapeutics LTD

Lenaic Nathanael Teyssedou, PRINCIPAL ACCOUNTING OFFICER of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Mikhail Kalinichev, HEAD OF TRANSLATIONAL SCIENCE of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Jason Raleigh Nunn, a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Isaac Manke, a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Vincent Michael Lawton, a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Timothy Mark Dyer, CHIEF EXECUTIVE OFFICER and a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.

Timothy Mark Dyer, CEO of Addex Therapeutics Ltd, has filed an amendment to Schedule 13D detailing his beneficial ownership of 19,165,714 shares, representing 9.01% of the company, following a reduction in option strike prices.

Timothy Mark Dyer, CEO of Addex Therapeutics, has updated his beneficial ownership filing, now holding approximately 8.89% of the company's shares following recent share dilution.

Timothy Mark Dyer, CEO of Addex Therapeutics Ltd., has increased his beneficial ownership in the company to 12.94% through a combination of share acquisitions, option exercises, and compensation.